 CAMBRIDGE, Mass., May 04, 2022 GLOBE NEWSWIRE -- Verve Therapeutics, a biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, announced that Sekar Kathiresan, M.D., co-founder and chief executive officer, will participate in the following May investor conferences: 